Combination of nateglinide with thiazolidinediones in Type 2 diabetes

References

• Katsilambros N, Tentolouris N. Type 2 diabetes: an overview. In: Textbook of Diabetes (Volume 1 [3rd edition]). Pickup JC, Gareth W (Eds). Blackwell Science Ltd, Oxford, UK 4.1–4.19 (2003).
   Google Scholar
• Szoke E, Gerich JE. Role of impaired insulin secretion and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. Compr. Ther.31(2), 106–112 (2005).
   PubMedGoogle Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes 1995–2025: prevalence, numerical estimates and projections. Diabetes Care21(9), 1414–1431 (1998).
   PubMed Web of Science ®Google Scholar
• Reimann M, Bonifacio E, Solimena M et al. An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol. Ther.121(3), 317–331 (2009).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Brindisi MC, Rabasa-Lhoret R. The prevention of Type 2 diabetes: what is the evidence? Minerva Endocrinol.30(3), 179–191 (2005).
   PubMedGoogle Scholar
• Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA281(21), 2005–2012 (1999).
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Kulkarni K. Management of Type 2 diabetes: oral agents, insulin, and injectables. J. Am. Diet Assoc.108(4), S29–S33 (2008).
   PubMed Web of Science ®Google Scholar
• Davidson JA. Treatment of the patient with diabetes: importance of maintaining target HbA(1c) levels. Curr. Med. Res. Opin.20(12), 1919–1927 (2004).
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann. Intern. Med.147(6), 386–399 (2007).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia46(1), 44–50 (2003).
   PubMed Web of Science ®Google Scholar
• Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with Type 2 diabetes. Vasc. Health Risk Manag.3(6), 797–807 (2007).
   PubMedGoogle Scholar
• Sato Y, Nishikawa M, Shinkai H et al. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diabetes Res. Clin. Prac.12(1), 53–60 (1991).
   PubMed Web of Science ®Google Scholar
• McClenaghan NH, Flatt PR. Physiological and pharmalogical regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diab. Obes. Metab.1(3), 1–14 (1999).
   Web of Science ®Google Scholar
• Hu S. Interaction of nateglinide with K(ATP) channel in β cells underlies its unique insulinotropic action. Eur. J. Pharmacol.442(1–2), 163–171 (2002).
   PubMed Web of Science ®Google Scholar
• Uto Y, Teno S, Iwamoto Y et al. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. Metabolism51(1), 20–24 (2002).
   PubMed Web of Science ®Google Scholar
• Laghmich A, Ladrière L, Malaisse-Lagae F et al. Long-term effect of glibenclamide and nateglinide upon pancreatic islet cell function in normal and diabetic rats. Pharmacol. Res.40(6), 475–482 (1999).
   Google Scholar
• Ball AJ, Flatt PR, McClenaghan NH. Acute and long-term effects of nateglinide on insulin secretory pathways. Br. J. Pharmacol.142(2), 367–373 (2004).
   Google Scholar
• Hu S, Wang S, Fanelli B et al. Pancreatic β-cell KATP channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J. Pharmacol. Exp. Ther.293(2), 444–452 (2000).
   PubMed Web of Science ®Google Scholar
• Bokvist K, Hou M, Bushard K et al. Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic α-cells. Eur. J. Pharmacol.386(1), 105–111 (1999).
   Google Scholar
• Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes54(1), 1–7 (2005).
   PubMed Web of Science ®Google Scholar
• Davies MJ. Post-prandial hyperglycemia and prevention of cardiovascular disease. Diabet. Med.22(Suppl.1), 1–21 (2005).
   Web of Science ®Google Scholar
• Maedler K, Carr RD, Bosco D et al. Sulfonylurea induced β-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab.90(1), 501–506 (2005).
   PubMed Web of Science ®Google Scholar
• Proks P, Ashcroft FM. Modelling K(ATP) channel gating and its regulation. Prog. Biophys. Mol. Biol.99(1), 7–19 (2009).
   Google Scholar
• Quast U, Stephan D, Bieger S, Ulrich R. The impact of ATP sensitive K channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes53(Suppl. 3), S156–S164 (2004).
   PubMed Web of Science ®Google Scholar
• Chachin M, Yamada M, Fujita A et al. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or a benzamido moiety, specifically inhibits pancreatic β-cell-type KATP channels. J. Pharmacol. Exp. Ther.304(3), 1025–1032 (2003).
   PubMed Web of Science ®Google Scholar
• McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly absorbed, short-acting insulinotropic agent. Clin. Pharmacokinet.43(2), 97–120 (2004).
   PubMed Web of Science ®Google Scholar
• Luzio SD, Anderson DM, Owens R. Effects of timing on administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. J. Clin. Endocrinol. Metab.86(10), 4874–4880 (2001).
   Google Scholar
• Keilson L, Mather S, Walter YH et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.85(3), 1081–1086 (2000).
   PubMed Web of Science ®Google Scholar
• Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J. Clin. Pharmacol.39(2), 172–179 (1999).
   PubMed Web of Science ®Google Scholar
• Dunning BE, Gutierrez C. Pharmacokinetics of nateglinide and repaglinide in Cynomolgus monkeys. Diabetes48, (1999) (Abstract 0104).
   Google Scholar
• Takesada H, Matsuda K, Ohtake R et al. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D phenylalanine-derivative hypoglycemic agent. Bioorg. Med. Chem.4(10), 1771–1781 (1996).
   PubMed Web of Science ®Google Scholar
• Weaver ML, Orwig BA, Rodriguez LC et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab. Dispos.29(4), 415–421 (2001).
   PubMed Web of Science ®Google Scholar
• Persaud SJ, Howell SL. The biosynthesis and secretion of insulin. In: Textbook of diabetes (Volume 1 [3rd Edition]). Pickup JC, Gareth W (Eds). . Blackwell Science Ltd, Oxford, UK 13.1–13.17 (2003).
   Google Scholar
• Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese Type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr. J.47(5), 639–641 (2000).
   PubMed Web of Science ®Google Scholar
• Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabet. Med.17(3), 225–229 (2000).
   PubMed Web of Science ®Google Scholar
• Carroll MF, Izard A, Riboni K, Burge MR, Schade DS. Control of postprandial hyperglycemia. Optimal use of short-acting insulin secretagogues. Diabetes Care25(12), 2147–2152 (2002).
   Google Scholar
• Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade D. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in Type 2 diabetes. J. Clin. Endocrinol. Metab.88(11), 5248–5254 (2003).
   PubMed Web of Science ®Google Scholar
• Barnett AH, Anderson DM, Shelley S et al. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycemia and hyperinsulinaemia in patients with Type 2 diabetes. Diabetes Obes. Metab.6(2), 104–113 (2004).
   PubMed Web of Science ®Google Scholar
• Lebovitz H. Insulin secretagogues: sulfonyrueas, repaglinide, and nateglinide. In: ADA’s Therapy for Diabetes Mellitus and Related Disorders. 164–175 (2004).
   Google Scholar
• Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in Type 2 diabetes. Diabetes Care23(11), 1660–1665 (2000).
   PubMed Web of Science ®Google Scholar
• Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care23(3), 349–353 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Gatlin MR, Shen SG, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in Type 2 diabetes. Diabetes Care25(9), 1529–1533 (2002).
   PubMed Web of Science ®Google Scholar
• Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with Type 2 diabetes. Curr. Med. Res. Opin.20(6), 883–889 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hassman DR, Madder RD et al. Repaglinide versus Nateglinide monotherapy. A randomized multicenter study. Diabetes Care27(6), 1265–1270 (2004).
   PubMed Web of Science ®Google Scholar
• Dashora UK, Sibal L, Ashwell SG, Home PD. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. Diabet. Med.24(4), 34434–34439 (2007).
   Google Scholar
• Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with Type 2 diabetes. Diabetes Obes. Metab.10(8), 652–660 (2008).
   PubMed Web of Science ®Google Scholar
• Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycemic control when added to metformin monotherapy: results of a randomized trial with Type 2 diabetes patients. Diabetes Obes. Metab.4(3), 177–186 (2002).
   PubMed Web of Science ®Google Scholar
• Ristic S, Collober-Maugeais C, Pacer E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet. Med.23(7), 757–762 (2006).
   PubMed Web of Science ®Google Scholar
• Ristic S, Collober-Maugeais C, Cressier F, Tang P, Pecher E. Nateglinide or gliclazide in combination with metformin for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes. Metab.9(4), 506–511 (2007).
   PubMed Web of Science ®Google Scholar
• Gerich J, Raskin P, Jean-Louis L et al. PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care28(9), 2093–2099 (2005).
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Fogari E et al. Nateglinide and glibenclamide metabolic effects in naive Type 2 diabetic patients treated with metformin. J. Clin. Pharm. Ther.34(1), 13–23 (2009).
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Fogari E et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive Type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern. Med.46(22), 1837–1846 (2007).
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, McGill J et al. Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care26(7), 2063–2068 (2000).
   Google Scholar
• Fontbonne AE, Eschwege F, Cambien JL et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose toleranceor diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia32(5), 300–304 (1989).
   PubMed Web of Science ®Google Scholar
• Ai M, Tanaka A, Kyoko O, Shomokado K. Favourable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with Type 2 diabetes. Diabetes Care29(5), 1180 (2006).
   Google Scholar
• Mori Y, Kuriyama G, Tajima N. Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with Type 2 diabetes assessment by meal tolerance test. Endocrine25(3), 203–206 (2004).
   PubMedGoogle Scholar
• Kitahara Y, Miura K, Kajioka T, Mine T. Suppressive effect of nateglinide on high fat diet-induced hepatic accumulation of triglycerides in Goto-Kakizaki rats. Presented at the 65th Annual Scientific Session of the American Diabetes Association. San Diego, CA, USA (2005).
   Google Scholar
• Dimitriadis G, Boutati E, Lambadiari V et al. Restoration of early insulin secretion after a meal in Type 2 diabetes: effects on lipid and glucose Metabolism Eur. J. Clin. Invest.34(7), 490–497 (2004).
   Google Scholar
• Tentolouris N, Boutati E, Karambakalis N et al. Acute Nateglinide administration in subjects with Type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis. Nutr. Metab. Cardiovasc. Dis.16(1), 6–12 (2005).
   Google Scholar
• Shimabukuro M, Higa N, Takasu N et al. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients. Diabet. Med.21(9), 983–986 (2004).
   Google Scholar
• Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus. Clin. Ther.24(10), 1690–1705 (2002).
   PubMed Web of Science ®Google Scholar
• Savage DB. PPAR γ as a metabolic regulator: insights from genomics and pharmacology. Expert Rev. Mol. Med.7(1), 1–16 (2005).
   Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med.53, 409–435 (2002).
   PubMed Web of Science ®Google Scholar
• Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science294(5548), 1866–1670 (2001).
   PubMed Web of Science ®Google Scholar
• Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor g and metabolic disease. Annu. Rev. Biochem.70, 341–367 (2001).
   PubMed Web of Science ®Google Scholar
• Berger JP, Petro AE, Macnaul KL et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein-gamma selective modulator. Mol. Endocrinol.17(4), 662–676 (2003).
   PubMed Web of Science ®Google Scholar
• Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res.49(10), 497–505 (2000).
   PubMed Web of Science ®Google Scholar
• Barbier O, Torra IP, Duguay Y et al. Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol.22(5), 717–726 (2002).
   PubMed Web of Science ®Google Scholar
• Duez H, Chao YS, Hernandez M et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem.277(50), 48051–48057 (2002).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet357(9260), 905–910 (2001).
   PubMed Web of Science ®Google Scholar
• Okuno A, Tamemoto H, Tobe K et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest.101(6), 1354–1361 (1998).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab.87(6), 2784–2791 (2002).
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated Type 2 diabetic patients. J. Clin. Endocrinol. Metab.89(1), 200–206 (2004).
   PubMed Web of Science ®Google Scholar
• Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with Type 2 diabetes. Diabetes51(3), 797–802 (2002).
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with Type 2 diabetes. Diabetes52(6), 1364–1370 (2003).
   PubMed Web of Science ®Google Scholar
• Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with Type 2 diabetes. Diabetes53(8), 2169–2176 (2004).
   PubMed Web of Science ®Google Scholar
• Sutinen J, Häkkinen A-M, Westerbacka J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study. Antivir. Ther.8(3), 199–207 (2003).
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. J. Biol. Chem.277(40), 37487–37491 (2002).
   PubMed Web of Science ®Google Scholar
• Peraldi P, Spiegelman B. TNF-α and insulin resistance: summary and future prospects. Mol. Cell. Biochem.182(1–2), 169–175 (1998).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature409(6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science294(5549), 2166–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Tsapogas P. Treatment of diabetes with pills. Thiazolidinediones. In: Diabetes in Clinical Practice. Questions and Answers from Case Studies. Katsilambros N, Diakoumopoulou E, Ioannidis I et al. (Eds). Wiley Publishers, West Sussex, UK 341–371 (2006).
   Google Scholar
• Kirchheiner J, Roots I, Goldammer M et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet.44(12), 1209–1225 (2005).
   PubMed Web of Science ®Google Scholar
• Wallace TM, Matthews DR. The drug treatment of Type 2 diabetes. Oral agents. Thiazolidinediones. In: Textbook of Diabetes (Volume 2). Pickup JC, Williams G (Ed.) Blackwell Publishing, MA, USA 45.11–45.13 (2006).
   Google Scholar
• Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and nonesterified fatty acid metabolism in Type 2 diabetic patients. Diabetologia44(12), 2210–2219 (2001).
   PubMed Web of Science ®Google Scholar
• Barnett AH. Redefining the role of thiazolidinediones in the management of Type 2 diabetes. Vasc. Health Risk Manag.5(1), 141–151 (2009).
   PubMedGoogle Scholar
• Acharya D, Falik R. Cardiovascular effects of thiazolidinediones: a review of the literature. South. Med. J.102(1), 51–56 (2009).
   PubMed Web of Science ®Google Scholar
• Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in Type 2 diabetes: theoretical consideration and therapeutic potential. Vasc. Health Risk Manag.4(6), 1221–1227 (2008).
   PubMedGoogle Scholar
• Mikhail N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of Type 2 diabetes. Expert Opin. Investig. Drugs17(6), 845–853 (2008).
   PubMed Web of Science ®Google Scholar
• Viberti G, Khan SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed Type 2 diabetes. Diabetes Care25(10), 1737–1743 (2002).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland EJA et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes: a randomized trial of pioglitazone: the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events). Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met-TZD). Diabetes Care32(7), 1224–1230 (2009).
   PubMed Web of Science ®Google Scholar
• Fonseca V, Grunberger G, Shen S, Foley JE. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care26(6), 1685–1690 (2003).
   PubMed Web of Science ®Google Scholar
• El-Batran SA, Abdel-Salam OM, Nofal SM, Baiuomy AR. Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. Pharmacol. Res.53(1), 69–74 (2006).
   Google Scholar
• Zawalich WS, Tesz G, Zawalich KC. Contrasting effects of nateglinide and rosiglitazone on insulin secretion and µ activation. Metabolism52(11), 1393–1399 (2003).
   Google Scholar
• Chia CW, Egan JM. Incretin-based therapies in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.93(10), 3703–3716 (2008).
   PubMed Web of Science ®Google Scholar